This editorial refers to 'A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score' † , by Z. Hijazi et al., on page 477.
Assessing risk of morbidity and mortality is an important aspect of caring for patients with heart disease that guides patient counselling and implementation of therapies. As the pathophysiological mechanisms involved in cardiovascular disease are multiple and complex, combining factors that reflect different components of the pathophysiology into a risk score can help provide an overall indication of risk. Ideally a clinical risk score is comprised of data that are readily available to clinicians. Most of the risk scores for predicting stroke or bleeding in atrial fibrillation (AF) follow this rule (i.e. CHADS-VASC, HAS-BLED, ORBIT, and ATRIA). [1] [2] [3] [4] In this issue of the journal, Dr Hijazi and colleagues 5 have derived a clinical risk score, the ABC death risk score, which includes measurement of GDF-15 (growth differentiation factor 15)-a biomarker recently made available for clinical laboratories. The results of their study leave us to consider the questions of whether our hospitals and clinics should make the investment to begin measuring GDF-15, and would a risk score to predict mortality in anti-coagulated patients with AF be useful to our practice. In this study, data from 14 611 participants enrolled in the ARISTOTLE trial (apixaban vs. warfarin) were used to derive a risk score to predict all-cause mortality. Using 13 standard clinical variables, 4 standard biomarkers, and GDF-15, a backward elimination algorithm selected 5 variables to include in the final model [age, congestive heart failure, troponin, brain natriuretic peptide (BNP), and GDF-15]. The model predicted all-cause mortality with an impressive c-statistic of 0.74 [95% confidence interval (CI) 0.73-0.76] in the derivation cohort and 0.74 in an independent validation cohort (the RE-LY trial; dabigatran vs. warfarin). This model is called the ABC death risk score, and along with the ABC bleeding and ABC stroke risk scores, is the third clinical risk score proposed by Dr Hijazi and colleagues using data from the ARISTOTLE Biomarker Sub-study ( Figure 1 ). 6, 7 Interestingly, they also show that the present score performed better than a comprehensive model of only clinical variables [cstatistic of 0.68 (95% CI 0.66-0.70)], demonstrating the potential power for quantitative biomarkers to improve risk prediction significantly. For some biomarkers there is a clear pathophysiological link by which they add valuable information about disease severity compared with the binary definitions used for clinical variables. For example, in the ABC death risk score, the addition of BNP levels presumably helped to distinguish between the low-risk well-compensated heart failure patients and the higher risk volume-overloaded heart failure patients. Similarly, troponin levels helped differentiate the patients with prior myocardial infarction (MI) who were completely revascularized vs. those with severe residual obstructive coronary artery disease. Less obvious, however, is the method by which GDF-15 levels improved the ability of the ABC death risk score to predict mortality in AF.
For readers without a special interest in biomarkers, GDF-15 may be unfamiliar. Originally called macrophage inhibitory cytokine (MIC-1), it was described over two decades ago. It has structural similarities to proteins of the transforming growth factor-beta (TGF-b) superfamily, but actually represents a distinct class of its own. It is up-regulated by pro-inflammatory cytokines (e.g. interferon-c, interleukin-1, TGF-b) and is believed to inhibit the later phases of macrophage activation, thereby exerting an overall anti-inflammatory effect. 8 While GDF-15/MIC-1 remains incompletely understood, levels of circulating GDF-15 can be viewed as a measure of systemic inflammation and oxidative stress. Disorders such as hypertension, obesity, diabetes, and vascular disease are well established risk factors for AF, and there is substantial evidence that inflammation and oxidative stress are major mechanisms by which these disorders promote AF pathogenesis. [9] [10] [11] From this perspective it can be speculated that GDF-15 may be a quantitative measure of the severity and cumulative effect of a variety of co-morbidities associated with mortality risk in AF (hypertension, obesity, diabetes, and vascular disease). GDF-15 has been associated with bleeding risk and has also been A potentially interesting signal in the present report is the lower mortality with apixaban compared with warfarin in the subgroup with the highest ABC death risk scores. Analysis of the specific causes of death stratified by apixaban vs. warfarin would be of interest. Based on the main results of ARISTOTLE, it would not be surprising if apixaban therapy reduced mortality through a reduction in bleeding or systemic thrombo-embolism/stroke, but an association with any other specific cause of death would be unexpected and open new and potentially exciting lines of investigation.
What will be the clinical utility of the ABC death risk score in daily practice? Risk assessment is used to guide implementation of therapies to reduce risk. This strategy requires the clinician to balance the patient's risk with the efficacy, risk, and costs of therapy. Therapies are largely directed at specific targets, based on pathophysiology, and ideally have benefit that has been confirmed in prospective trials. While the ABC death risk score is convincingly demonstrated to predict mortality in AF patients, it does not refine our ability to select therapy, and may, therefore, be less directly useful than the ABC stroke risk and ABC bleeding risk scores which clearly inform the decision of whether to anticoagulate, and for which substantial data are available to assess risks and benefits. Mechanisms other than thrombo-embolism and bleeding contribute to mortality in patients with AF. The relative contribution of myocardial ischaemia, heart failure, and arrhythmias to deaths predicted by an ABC death risk score is not known. Due to the common association of AF with arterial vascular disease, hypertension, and heart failure, an assessment for these disorders and implementation of therapies that have been shown to have benefit should be a routine component of caring for patients with AF. 14 The recognition that AF is associated with increased mortality when paired with these conditions adds additional emphasis to this approach, and an elevated ABC death risk score could further motivate aggressive preventive therapies as appropriate for the other associated conditions present. Whether escalating therapies based on a general score that predicts total and cardiovascular mortality is warranted requires further study.
